PBH icon

Prestige Consumer Healthcare

84.53 USD
+0.11
0.13%
Updated May 22, 1:07 PM EDT
1 day
0.13%
5 days
-2.96%
1 month
5.36%
3 months
-0.65%
6 months
-0.38%
Year to date
8.76%
1 year
30.59%
5 years
100.40%
10 years
93.70%
 

About: Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

Employees: 600

0
Funds holding %
of 7,245 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

117% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 23

100% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 4 (+2) [Q1 2025]

7% more capital invested

Capital invested by funds: $4.1B [Q4 2024] → $4.39B (+$299M) [Q1 2025]

6% more funds holding

Funds holding: 333 [Q4 2024] → 354 (+21) [Q1 2025]

2.94% less ownership

Funds ownership: 106.18% [Q4 2024] → 103.24% (-2.94%) [Q1 2025]

32% less repeat investments, than reductions

Existing positions increased: 104 | Existing positions reduced: 152

79% less call options, than puts

Call options by funds: $9K | Put options by funds: $43K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$97
15%
upside
Avg. target
$97
15%
upside
High target
$97
15%
upside

1 analyst rating

positive
0%
neutral
100%
negative
0%
RBC Capital
15%upside
$97
Sector Perform
Maintained
21 Mar 2025

Financial journalist opinion

Based on 10 articles about PBH published over the past 30 days

Positive
Zacks Investment Research
1 week ago
PBH vs. ESLOY: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks presents investors with the better value opportunity right now?
PBH vs. ESLOY: Which Stock Should Value Investors Buy Now?
Positive
Zacks Investment Research
1 week ago
Prestige Consumer Stock Up 8% Since Q4 Earnings Beat, Margin Increase
PBH experiences steady international growth in the fourth quarter, banking on strong sales of the Hydralyte brand.
Prestige Consumer Stock Up 8% Since Q4 Earnings Beat, Margin Increase
Neutral
Seeking Alpha
1 week ago
Prestige Consumer Healthcare Inc. (PBH) Q4 2025 Earnings Call Transcript
Prestige Consumer Healthcare Inc. (NYSE:PBH ) Q4 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Phil Terpolilli – Vice President, Investor Relations and Treasury Ron Lombardi – Chairman, President and Chief Executive Officer Christine Sacco – Chief Financial Officer and Chief Operating Officer Conference Call Participants Rupesh Parikh – Oppenheimer Susan Anderson – Canaccord Keith Devas – Jefferies Glenn West – William Blair Anthony Lebiedzinski – Sidoti & Company Doug Lane – Water Tower Research Operator Good day, and thank you for standing by. Welcome to the Prestige Consumer Healthcare's Fourth Quarter 2025 Earnings Conference Call.
Prestige Consumer Healthcare Inc. (PBH) Q4 2025 Earnings Call Transcript
Neutral
Zacks Investment Research
2 weeks ago
Prestige Consumer Healthcare (PBH) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Prestige Consumer Healthcare (PBH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Prestige Consumer Healthcare (PBH) Reports Q4 Earnings: What Key Metrics Have to Say
Positive
Zacks Investment Research
2 weeks ago
Prestige Consumer Healthcare (PBH) Tops Q4 Earnings and Revenue Estimates
Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.30 per share. This compares to earnings of $1.02 per share a year ago.
Prestige Consumer Healthcare (PBH) Tops Q4 Earnings and Revenue Estimates
Neutral
GlobeNewsWire
2 weeks ago
UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings
TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) --  Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025.
UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings
Neutral
GlobeNewsWire
2 weeks ago
Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings
TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) --  Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025.
Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings
Neutral
Zacks Investment Research
2 weeks ago
Insights Into Prestige Consumer Healthcare (PBH) Q4: Wall Street Projections for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Prestige Consumer Healthcare (PBH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Insights Into Prestige Consumer Healthcare (PBH) Q4: Wall Street Projections for Key Metrics
Positive
Zacks Investment Research
3 weeks ago
Prestige Consumer Healthcare (PBH) Reports Next Week: Wall Street Expects Earnings Growth
Prestige Consumer Healthcare (PBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prestige Consumer Healthcare (PBH) Reports Next Week: Wall Street Expects Earnings Growth
Positive
Zacks Investment Research
3 weeks ago
PBH or ABT: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
PBH or ABT: Which Is the Better Value Stock Right Now?
Charts implemented using Lightweight Charts™